ivWatch Grows Global Intellectual Property Portfolio with Additional Patent Grants

Australian and Japanese grants bring owned patents to nine

HAMPTON, Va., December 5, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently had two patent applications granted by the Australian and Japanese Patent Offices expanding the company’s intellectual property (IP) portfolio. ivWatch now owns nine patents around the world corresponding to their proprietary breakthrough technologies.

The granting of Australian Patent No. 2013257212 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be independent of the dressings that cover infusion sites during IV therapy or integrated within. This Australian grant comes on the heels of the company announcing an Australia and New Zealand distribution agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories.

“Our research and development efforts allow us to continually innovate,” said Gary Warren, president and CEO of ivWatch. “Protecting the resulting breakthroughs of those efforts as we expand into new markets ensures patients have highly effective early detection technology no matter where they are receiving medical treatment.”

ivWatch patented technology addresses patient harm caused by peripheral IV infiltration and extravasation events head-on, something many medical device companies and health care systems have attempted over the past 30 years. ivWatch succeeded by solving motion issues related to continuous peripheral IV therapy monitoring.

This core technology is related to ivWatch’s fourth Japanese patent grant, Registration No. 6396904, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors where patient motion produces unwanted noise. By mitigating the effects of changing tissue blood volume, the system minimizes “false” notifications. Reliable early detection of these events paves the way for a new standard of care to minimize injuries associated with the common complication of IV therapy.

To learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCwww.ivwatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

 

ivWatch Announces Two Senior Executives to Strengthen Growth

New roles include finance and research & development department leaders

HAMPTON, Va., November 27, 2018 – ivWatch, a medical device and biosensor technology company specializing in continuous monitoring solutions for the early detection of intravenous (IV) infiltrations and extravasations, is pleased to announce two new additions to its executive leadership team with the appointments of Nikki Lowe as chief financial officer and Jaclyn Lautz, Ph.D. as vice president of research & development. These executive and senior leadership positions will strengthen the company’s focus on global growth and increase the pace of their biosensor platform development.

“We’re thrilled to have two talented senior executives join our mission to keep more patients safe from preventable medical harm,” said Gary Warren, president and CEO of ivWatch. “Nikki and Jaclyn both have perfectly suited skills and insights to jump in and build their strategies supporting our roadmap and continued investment in new health care innovations.”

Nikki Lowe, Chief Financial Officer

As a member of the company’s executive management team and a direct report to President and CEO Gary Warren, Lowe will have primary responsibility for planning, implementing, managing and controlling all financial-related activities of the company. This will include accounting, finance, forecasting, strategic planning and manufacturing financial analysis.

Lowe has successfully led diverse global accounting functions for multi-divisional companies. She has more than 10 years of executive leadership experience, which includes mergers and acquisitions, financial operations, investor relations and strategic planning reporting and analysis in software and consumer industries. Most recently, she served as an Executive Vice President of Finance for Perfect Commerce Holdings, a global sourcing and procurement software solutions company that she helped facilitate its sale to a UK public entity.

Prior to that role, Lowe served in various accounting and finance leadership roles at top companies in Newport News, Va. including Spiegel, Newport News and Shape FX brands and Ferguson Enterprises. A certified public and global management accountant, Lowe also held senior associate positions in her early career at KPMG and Clifton Gunderson after receiving a bachelor’s degree in accounting from the University of Illinois in Springfield.

Jaclyn Lautz Ph.D., Vice President, Research & Development

As a senior leader, Lautz will oversee all product development and innovation efforts for the company. Her role in this new position includes directing the engineering teams on the design and development of new products and working across departments to bring new products to the market. She will also report directly to Warren.

Lautz rejoins ivWatch from Pricewaterhouse Coopers (PwC) where she was an advisory manager in the pharmaceutical and life sciences operations practice. From 2014-2017, Lautz was ivWatch’s Director of Regulatory Affairs & Quality Assurance, where she was involved with nearly every department in the company from research and development to post-market surveillance. Previous career experiences include six years working as an engineering innovation fellow at Applied Research Associates, a scientific research and engineering company, a biomedical engineer at Semprus Biosciences and a software engineer at an orthopedic clinic.

Lautz has a Ph.D. in mechanical engineering & materials science from Duke University where she worked with industry partners, Siemens and Boston Scientific, on new medical devices and treatment strategies for urological diseases. She holds a B.S. in biomedical engineering from Boston University. Her work is published in several physics and medical journals.

To learn more about ivWatch leadership, visit www.ivwatch.com/about-us/#leadership-team.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. www.ivwatch.com

MEDIA CONTACT

Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Extends Patient Monitor to International Markets

HAMPTON, Va., November 14, 2018 – ivWatch, the only provider of continuous patient monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, announces a new international partner to manage distribution to support market expansion outside of the United States.

Following the CE marking of the ivWatch Model 400, the company signed an agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories, as its distributor for Australia and New Zealand.

“Our entry into these markets is a response to growing awareness and clinical demand,” said Scott Hensley, vice president of sales and business development at ivWatch. “We are now poised to meet the ongoing customer requests for our technology as they seek cutting-edge solutions to address the global problem of patient harm caused by peripheral IV infiltration.”

Upon completion of regulatory approval requirements for these markets, the ivWatch Model 400 system will be available for the new distributor to introduce clinicians to continuous monitoring to improve patient safety. The company has obtained ISO 13485:2016 Certification through the Medical Device Single Audit Program (MDSAP). MDSAP is a global standard for medical device quality management systems in which many international partners participate including the Therapeutic Goods Administration of Australia.

“Australia is home to vascular access leaders who are undertaking significant scientific research focused on combating IV therapy complications internationally,” said Paul Williams, director of New Medical. “We’re excited to put our technical teams in place to serve the needs of our customers. Our progressive health care market is equipped to make reliable early detection and notifications of this common IV complication a part of their efforts toward improving patient safety and outcomes.”

This week, ivWatch is attending MEDICA, the World Forum for Medicine, as part of their commitment to sharing their innovative technology with the global community. ivWatch will be a part of the U.S. Commercial Service’s Corporate Executive Office (CEO) Program located in Hall 16, C04 USA CEO Center.

To learn more about ivWatch and their industry partners, visit www.ivwatch.com/about-us/partnerships/.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCwww.ivwatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: Accelerating Device Acceptance

ivWatch CNO Talks Training Tips During Device Installations

ivWatch Chief Nursing Officer, Susan Brown, offers insights on device implementation in the Medical Device and Diagnostic Industry (MD+DI) article, “Device Implementation Sets the Stage for Successful Adoption.” She states aligned institution and device manufacturer collaboration is essential to bring in new innovations to support the ultimate goal of bettering outcomes and care. Read the full article here.

ivWatch Enters into Agreement with ICU Medical to Offer Customers Interoperability

Agreement will allow ivWatch technology integration into new devices and systems

HAMPTON, Va., October 4, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, entered into a long-term development and commercialization agreement with ICU Medical, a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications. The collaboration will offer a way forward for Electronic Health Records (EHR) interoperability by connecting the two companies’ systems in order to exchange and use high-quality data.

“Our two companies can optimize our services with the multi-dimensional interchange of data sets to not just improve the continuum of care, but also patient outcomes,” said Gary Warren, president and CEO of ivWatch. “ICU Medical’s expertise in developing IV-EHR interoperability solutions will support our mission to help advance patient safety.”

The current health care atmosphere emphasizes both efficiency and quality, and clinicians are faced with the challenge of doing more with less.

“Interoperability provides significant value to health care organizations with improvements in safety and efficiency,” said Matthew Hutchings, ICU Medical’s senior director of marketing and innovation for IV Systems. “We see a great opportunity to enhance these benefits through our relationship with ivWatch.”

Industry best practices of peripheral IV insertion, maintenance and assessment have been unable to completely address the issue of infiltration/extravasation. A new standard of care is required to minimize injuries associated with this common complication of IV therapy. The use of continuous monitoring technology for earlier identification will more aggressively take on this potential for patient harm.

“Interoperability is essential for customers and often a requirement during the buying decision process,” said Scott Hensley, vice president of sales and business development at ivWatch. “With ivWatch and ICU Medical working together, we can reach more patients and assist institutions with keeping patients safe from preventable harm and drug delivery errors.”

To learn more about ivWatch, visit www.ivWatch.com.

About ICU Medical:
ICU Medical, Inc. (Nasdaq: ICUI) is one of the world’s leading pure-play infusion therapy companies with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps, dedicated and non-dedicated IV sets and needlefree connectors, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, the company manufactures automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for hazardous IV drugs, and cardiac monitoring systems to optimize patient fluid levels. ICU Medical is headquartered in San Clemente, California. On February 3, 2017, ICU Medical completed the acquisition of the Hospira Infusion Systems business from Pfizer. More information about ICU Medical, Inc. can be found at www.icumed.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. www.ivwatch.com

MEDIA CONTACTS

ivWatch: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ICU Medical, Inc.: Tom McCall, tmccall@icumed.com, 949-366-4368

ivWatch Continues to Expand Global Patent Portfolio

New European and Japanese grants bring total to seven owned patents 

HAMPTON, Va., October 2, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, received two patents granted by the European and Japanese Patent Offices expanding their intellectual property (IP) portfolio.

The granting of European Patent No. 2830488 provides protection of the geometry of optical components in a manner that maximizes signal response from deep tissue while minimizing the size of the sensor. This European grant comes on the heels of the company announcing the CE marking of the ivWatch Model 400, a medical device that provides early detection of a frequent and common IV therapy complication. The company is also pursuing this granting at the national stage in several countries as part of their global expansion plan.

“ivWatch continues to heavily invest in the research and development of our biosensor platform. This investment in our talented engineers, scientists and tooling has produced a rich intellectual property portfolio of applications and grants and is allowing a pipeline of great products to address unmet needs in medicine in a way that has never been done before,” said Gary Warren, president and CEO of ivWatch. “As we continue to execute on our global plan, we must protect our proprietary technology which has secured ivWatch’s position as a first, and only, technology of its kind.”

Japanese Patent Registration No. 6386643 is for a core technology for mitigating the effects of tissue blood volume changes. This is the third granted patent from Japan and corresponds to U.S. Patent No. 9,326,686, for solving motion issues related to continuous PIV therapy monitoring. This patent describes some methods used by ivWatch to extract meaningful signals from biosensors where patient motion produces unwanted noise. ivWatch’s unique method of mitigating the effects of changing tissue blood volume provides a system that minimizes “false” notifications and not contributing to the epidemic of alarm fatigue.

ivWatch now owns seven patents around the world corresponding to three core technologies. More than 90 utility patent applications have been filed to date, including 59 domestic patent applications, eight international patent applications and 26 regional/national applications.

To learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest